ArticleSurgical neurology international2026
Rescue clazosentan for symptomatic cerebral vasospasm following subarachnoid hemorrhage due to anterior cranial fossa dural arteriovenous fistula: A case report with serial angiographic evaluation.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vasospasms associated with dural arteriovenous fistula (dAVF)-related subarachnoid hemorrhage (SAH) are rare, and their management has not been well established. Clazosentan, a selective endothelin A receptor antagonist, is typically administered soon after an SAH to prevent cerebral vasospasms. However, the optimal timing remains controversial because of the risk of fluid retention and related complications. Here, we report the case of dAVF-related SAH in which clazosentan was introduced as rescue therapy to treat cerebral vasospasm. Case Description: A 61-year-old man presented with SAH caused by the rupture of a Borden type III dAVF in the anterior cranial fossa. Following surgical occlusion, intravenous fasudil hydrochloride was administered for vasospasm prophylaxis. However, severe bilateral anterior and middle cerebral artery vasospasms developed on day 10, accompanied by progressive somnolence. Intra-arterial fasudil hydrochloride administration provided limited and transient improvements. Clazosentan was subsequently introduced as rescue therapy and was continuously administered for 4 days. Angiography revealed marked vasodilatation, particularly in the distal vessels, following clazosentan administration. Although fluid retention was observed, the patient was administered diuretics without clinical respiratory deterioration. No cerebral infarction occurred, and the patient was transferred with a favorable outcome (modified Rankin Scale score of 1). Conclusion: This case suggests that rescue administration of clazosentan may have contributed to improvement as part of multimodal vasospasm management following dAVF-related SAH, with vasodilatory effects comparable to those observed in aneurysmal SAH cases. Furthermore, short-term rescue administration of clazosentan may be tolerable in patients at high risk of fluid retention-related complications when careful fluid management and appropriate diuretic use are implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.